OSE Immunotherapeutics (OSE) is a drug developer that focuses on both oncology and immune disorders, with an R&D pipeline diversified across different indications and mechanisms of action. Long-term collaborations with top research institutions enable the company to identify novel targets in a cost-effective and time-efficient manner, and develop products for R&D and out-licensing. The success of this model is demonstrated by several commercial partnerships, including a deal with Boeh
06 Dec 2018
OSE Immunotherapeutics - Immunotherapy research engine
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
OSE Immunotherapeutics - Immunotherapy research engine
OSE Immunotherapeutics SA (OSE:PAR) | 0 0 0.0%
- Published:
06 Dec 2018 -
Author:
Dr Jonas Peciulis -
Pages:
23
OSE Immunotherapeutics (OSE) is a drug developer that focuses on both oncology and immune disorders, with an R&D pipeline diversified across different indications and mechanisms of action. Long-term collaborations with top research institutions enable the company to identify novel targets in a cost-effective and time-efficient manner, and develop products for R&D and out-licensing. The success of this model is demonstrated by several commercial partnerships, including a deal with Boeh